



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON 29 AUGUST 2025 (OR ANY ADJOURNMENT THEREOF)

I/We ^(Note 1) _____
of _____
being the registered holder(s) of _____ ^(Note 2) shares of HK\$0.01 ("Shares") each in the share capital of Innovative Pharmaceutical Biotech Limited (the "Company"), **HEREBY APPOINT** ^(Note 3) _____ or failing him, the chairman of the annual general meeting (the "Meeting") of the Company as my/our proxy at the Meeting to be held at The Function Room 1-2, 2/F The Harbourview, 4 Harbour Road, Wanchai, Hong Kong on Friday, 29 August 2025 at 11:00 a.m. (and at any adjournment thereof) and to vote on my/our behalf in respect of the resolutions as indicated below ^(Note 4):

ORDINARY RESOLUTIONS ^(Note 5)		FOR ^(Note 4)	AGAINST ^(Note 4)
1.	To receive and adopt the audited financial statements and the reports of the directors (the "Directors") and of the auditors of the Company for the year ended 31 March 2025.		
2.	(i) To re-elect Dr. Yeung Yung as an executive Director;		
	(ii) To re-elect Mr. Gao Yuan Xing as an executive Director;		
	(iii) To re-elect Mr. Tang Rong as an executive Director;		
	(iv) To re-elect Ms. Qi Shujuan as an executive Director;		
	(v) To re-elect Dr Long Fan as an executive Director;		
	(vi) To re-elect Dr. Wu Ming as an executive Director;		
	(vii) To re-elect Mr. Zhang Shen as an executive Director;		
	(viii) To re-elect Mr. Zhang Yi as a non-executive Director;		
	(ix) To re-elect Ms. Chen Weijun as an independent non-executive Director;		
	(x) To re-elect Dr. Xia Tingkan, Tim as an independent non-executive Director;		
	(xi) To re-elect Ms. Sun Sizheng as an independent non-executive Director; and		
	(xii) To authorise the board of Directors to fix the Directors' remuneration.		
3.	To re-appoint SFAI (HK) CPA Limited as the Company's auditors and to authorise the board of Directors to fix their remuneration.		
4.	To give a general mandate to the Directors to allot, issue and otherwise deal with additional Shares not exceeding 20% of the total number of the issued shares of the Company as at the date of this resolution.		
5.	To give a general mandate to the Directors to buy back the Shares not exceeding 10% of the total number of the issued shares of the Company as at the date of this resolution.		
6.	To extend the general mandate granted to the Directors to issue the Shares pursuant to the foregoing resolution no. 4 by a total number of Shares bought back by the Company pursuant to the foregoing resolution no. 5.		
7.	The authorised share capital of the Company be increased from (i) HK\$500,000,000 divided into 50,000,000,000 shares of HK\$0.01 each to (ii) HK\$1,200,000,000 divided into 120,000,000,000 shares of HK\$0.01 each, by the creation of an additional 70,000,000,000 shares of HK\$0.01 each.		
SPECIAL RESOLUTION ^(Note 5)		FOR ^(Note 4)	AGAINST ^(Note 4)
8.	Subject to and conditional upon the approval of the Registrar of Companies in Bermuda being obtained, the English name of the Company be changed from "Innovative Pharmaceutical Biotech Limited" to "Starcoin Group Limited", and the Chinese name of "星太鏈集團有限公司" to be adopted as the secondary name of the Company in place of the existing name of "領航醫藥及生物科技有限公司".		

Dated this _____ day of _____ 2025.

Signature: _____

Notes:

1. Full name(s) and address(es) to be inserted in **BLOCK LETTERS**.
2. Please insert the number of Shares registered in your name(s). If no number is inserted, this form of proxy will be deemed to relate to all the Shares in the share capital of the Company registered in your name(s).
3. Please insert the name and address of the proxy desired. **IF NO NAME IS INSERTED, THE CHAIRMAN OF THE MEETING WILL ACT AS YOUR PROXY.**
4. **IMPORTANT: IF YOU WISH TO VOTE FOR A RESOLUTION, PLEASE TICK “✓” THE APPROPRIATE BOX MARKED “FOR”. IF YOU WISH TO VOTE AGAINST A RESOLUTION, PLEASE TICK “✓” THE APPROPRIATE BOX MARKED “AGAINST”.** Failure to complete any of the boxes will entitle your proxy to vote or abstain at his discretion. Your proxy will also be entitled to vote at his discretion on any resolution properly put to the Meeting other than those referred to in the notice convening the Meeting.
5. The full text of each resolution referred to above is set out in the notice of the Meeting dated 31 July 2025.
6. This form of proxy must be signed by you or your attorney duly authorized in writing or, in the case of a corporation, must be either under its common seal or under the hand of an officer or attorney duly authorized.
7. In the case of joint holders, the vote of the senior who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint holder(s), and for this purpose seniority will be determined by the order in which the names stand in the register of members of the Company.
8. To be valid, this form of proxy, together with the power of attorney (if any) or other authority (if any) under which it is signed or a notarially certified copy thereof, must be deposited at the Company's branch share registrar and transfer agent in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 48 hours before the time appointed for holding the Meeting or any adjournment thereof.
9. The proxy need not be a member of the Company but must attend the Meeting in person to represent you.
10. Completion and delivery of this form of proxy will not preclude you from attending and voting at the Meeting (or any adjournment thereof) if you so wish and in such event, this form of proxy shall be deemed to have been revoked.

PERSONAL INFORMATION COLLECTION STATEMENT

Your supply of your and your proxy's (or proxies') name(s) and address(es) is on a voluntary basis for the purpose of processing your request for the appointment of a proxy (or proxies) and your voting instructions for the Meeting of the Company (the "Purposes"). We may transfer your and your proxy's (or proxies') name(s) and address(es) to our agent, contractor, or third party service provider who provides administrative, computer and other services to us for use in connection with the Purposes and to such parties who are authorized by law to request the information or are otherwise relevant for the Purposes and need to receive the information. Your and your proxy's (or proxies') name(s) and address(es) will be retained for such period as may be necessary to fulfil the Purposes. Request for access to and/or correction of the relevant personal data can be made in accordance with the provisions of the Personal Data (Privacy) Ordinance and any such request should be in writing by mail to the Company/Tricor Investor Services Limited at the above address.